Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2022-11-21
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and
bevacizumab and to see how well they work in treating patients with previously untreated
kidney cancer that has spread to other places in the body (metastatic). Pazopanib
hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking
blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth
by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride
together with bevacizumab may kill more tumor cells.